APA (7th ed.) Citation

Díaz-García, C., Serrano-Villar, S., Morales, A. G. G. d., Güerri-Fernández, R., Pérez-Somarriba, J., Palomino, S. S., . . . Martínez-Sanz, J. (2025). Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment. Open Forum Infectious Diseases, 12(11), 1. https://doi.org/10.1093/ofid/ofaf626

Chicago Style (17th ed.) Citation

Díaz-García, Claudio, et al. "Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment." Open Forum Infectious Diseases 12, no. 11 (2025): 1. https://doi.org/10.1093/ofid/ofaf626.

MLA (9th ed.) Citation

Díaz-García, Claudio, et al. "Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment." Open Forum Infectious Diseases, vol. 12, no. 11, 2025, p. 1, https://doi.org/10.1093/ofid/ofaf626.